



Harbour BioMed 2026 Interim Results

August, 2026

HBM HOLDINGS-B

2142.HK



Agenda

01

Harbour BioMed 2026H1

Three Growth Engines Working in Synergy, Delivering a Seventh Consecutive Half-Year of Profitability

Jingsong Wang
MD PhD

02

Harbour Therapeutics

Substantial Market for Mid-to-Late-Stage Assets, Advancing Toward Global Registrational Trials

Jingsong Wang
MD PhD

03

Nona Biosciences

Global Antibody R&D Infrastructure, Driving High-Growth with “AI+Automation”

Di Hong
DBA

04

Business Model, Partnerships & Financial Update

Global Leader in The New Paradigm of Collaboration, Driving a Sustainable and Profitable Business Model

Youchen Chen
MBA

05

Future Outlook

Toward Vision 2028 – Building a Global Leading Platform-Based Biopharma Group

Jingsong Wang
MD PhD





Disclaimer

This presentation has been prepared by HBM Holdings Limited (the “Company”) solely for informational purposes and does not constitute an offer to sell or issue or the solicitation of an offer to buy or acquire securities of the Company in any jurisdiction or an inducement to enter into investment activity, nor may it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever.

This document has been prepared by the Company solely for use at this presentation. The information contained in this presentation has not been independently verified. No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or the opinions contained herein. None of the Company or any of its affiliates, directors, officers, advisors or representatives will be liable (in negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising from or in connection with this presentation.

This presentation contains statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ from those in the forward-looking statements as a result of various factors and assumptions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this presentation, except as required by law.

Harbour BioMed 26H1: Three Growth Engines Working in Synergy, Delivering a Seventh Consecutive Half-Year of Profitability

One of The Few Biopharma Companies to Deliver a “Four-in-One” Combination of AI-Enabled Antibody Discovery Platform + Accelerating Clinical Advancement + Strategic MNC Partnerships + Sustained Profitability

Harbour Therapeutics

Drug Developer Leading Next-Gen Therapies in 4 Dedicated Areas



Porustobart

HBM4003 – Novel CTLA-4

\$1.2B+ NewCo Licensing Deal

25+ Programs with BIC/FIC

Potential Targeting \$100B+ Global Market

\$6B+ Peak Sales Potential across Core Mid-to-Late-Stage Assets

Nona Biosciences

AI-Enabled TechBio Empowering Global Therapeutic Innovation

Total Revenue¹ Achieved High Growth in 26H1

>\$46M (YoY ~4x)

Further Expanded Strategic Collaborations

Lonza **Link** ...
Cell Therapies

AI Antibody Discovery Platform²
Actively Advancing 40+ Programs

Global Co-Co & Licensing

Global Leader Driving the New Paradigm of Collaboration

Total BD Value

>\$13B

Steadily Advancing 10+ Co-Co Programs

AstraZeneca

Bristol Myers Squibb

HCAb⁴Platform Patent Victory

US Court Fully Upheld \$20.2M Damages Award



2026H1 Results

\$122M

(~RMB 834M)

YoY+21%


Total Revenue and Growth

\$71.6M

(~RMB 488M)

Adjusted³ Net Profit

■ Harbour BioMed AI: Building the Next-Gen AI Innovation System – From Antibody AI Model to Antibody Development to A Collaboration Ecosystem



Three Innovation Engines Driving Early Discovery to Clinical Development, Maximizing Value from Innovative Technology to Pipeline Products

Rich Early-Stage Platform Innovation Capability + Strategic Collaborations

Proprietary Technology Platforms

4 technology platform engines developing highly differentiated, innovative molecules



BsAb/TCE



TsAb



ADC



Oligo



AOC



mRNA

... ..

Innovation Engines

HARBOUR
BIOMED

HBM Early Research Institute¹

Co-Development

AstraZeneca

Bristol Myers Squibb

External Innovation
Projects

technology transfer from academic institutions & in-licensing, etc.

China's Clinical Translation Efficiency + High-Quality Global Collaborations

Clinical Translation



Building proprietary clinical development capabilities across multiple disease areas



I&I



Oncology



Obesity



CNS



Leveraging China's efficient R&D system to advance early clinical translation

NEU2005
Undisclosed Target

HBM7575
TSLP BsAb

HBM7004
B7H4 TCE

LET003
ACVR2A/2B

HBM2001
TL1AxIL23p19

HBM9013
CRH Neutralizing Antibody

Mid-to-Late-Stage Clinical Development

China Rights

HBM9378
TSLP mAb

HBM4003
CTLA-4 mAb

...

Accelerating China clinical development toward commercialization...

Out-Licensing
& Co-Development

AstraZeneca

HBM7022
CLDN18.2 TCE

Otsuka

HBM7020
BCMA TCE

MNC

moderna

mRNA
递送

Umoja

体内CAR-T
疗法

Biotech

Windward Bio

HBM9378
TSLP mAb

Solstice Oncology

NewCo

HBM4003
CTLA-4 mAb




~RMB 100B
(\$13B)

Total BD
Value since
Inception

HBM's Sustained BD Capability and BD Engine across Early Discovery, Translation, and Clinical Development

3+ Mid-to-Late-Stage Pipelines Aggregating >\$6B Peak Sales Potential with >5 BIC/FIC Innovative Programs to be Validated through Early PoC





Harbour's TSLP Partner Windward Bio

Seasoned Global Leadership Backed by Top-Tier Healthcare Investors



Pipeline

Program/Modality	IND	Phase I	Phase II	Phase III and beyond	Territory	Positioning/Status
WIN378/HBM9378* TSLP mAb Fully-Human Ultra-Long-Acting	<div>Moderate-to-Severe Asthma</div>			Ph2 data readout	GC & Other Countries **	• Ph2 interim data (2026Q3); Ph3 initiation (2026Q4)
	<div>COPD</div>					• Ph2 initiated in Jun.2026 (FPI)

Management Team



Luca Santarelli, MD
Founder, Chief Executive Officer,
and Board Chair



Omar Khwaja, MD, PhD
Chief Medical Officer



Claudia D'Augusta, PhD
Chief Financial Officer



Kevin Harris, MBA
Chief Operating Officer



Scott Applebaum
Chief Legal & Corporate
Development Officer



Investment Team




*Co-developed with Kelun Biotech
**Other countries including several Southeast and West Asian countries

HBM7575 (Ultra-Long-Acting TSLP BsAb): Phase I Initiated with Accelerating Patient Enrollment

HBM7575: Ultra-long-acting bispecific antibody with dual mechanisms for synergistic efficacy

- Dual mechanism of action :
 - by blocking the interaction between TSLP and its receptor, it inhibits TSLP-mediated signaling pathways and the activation of Th2 immune cells ;
 - binding to and blocking the undisclosed target generates a synergistic effect, overcoming resistance issues associated with TSLP single-target antibodies
- Engineered to possess an extended half-life and favorable developability, enabling **subcutaneous administration**
- Based on preclinical half-life data, the anticipated human half-life is expected to support dosing intervals of **more than three months**, positioning it as a potential best-in-class therapy
- Fully human TSLP bispecific with a **favorable immunogenicity profile** and early clinical validation



Phase I (NCT07488065)

Indication	Atopic Dermatitis
Enrollment	90 patients
Initiation Time	March 2026
Location	Shanghai
Clinical Plan	Randomized, double-blind, placebo-controlled, in two parts: <ul style="list-style-type: none">• Part 1 (Phase Ia): dose escalation in healthy subjects evaluating safety;• Part 2 (Phase Ib): proof-of-concept for efficacy, evaluating EASI-75 response rate at Week 16

Phase I (NCT07732023)


Indication	Asthma
Enrollment	36 patients
Initiation Time	July 2026
Location	Sichuan
Clinical Plan	Phase Ib: multicenter, randomized, double-blind, placebo-controlled, evaluating efficacy, PK/PD, and safety

■ ■ ■ Porustobart (HBM4003): A BIC-Potential Novel Anti-CTLA-4, Successfully Out-Licensed, with Global Clinical Trials Expected to Initiate in Near Term


HBM4003: Novel CTLA-4 Molecule with BIC Potential

- ❑ The world's first **fully human heavy chain-only (HCAb)** anti-CTLA-4 antibody to enter clinical development
- ❑ Deplete intra-tumoral Treg cells via **enhanced ADCC strategy**
- ❑ **Great safety profile** resulted from the reduced systemic drug exposure
- ❑ Huge potential for combination therapies: **positive efficacy** and safety data already reported from clinical trials in melanoma, colorectal cancer, neuroendocrine carcinoma, and hepatocellular carcinoma


MOA1: Checkpoint Inhibition



MOA2: T_{reg} Depletion



Solstice Oncology



Brianna M Lax., et al., Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodies. *PNAS*. 2023 Aug;120(31)

Outstanding MSS CRC clinical data with successful out-licensing in Feb. 2026

2025.10

MSS CRC Phase II data readout

2026H1

Major Progress in Global Development

2026.02

Ex-GC out-licensing & NewCo with Solstice Oncology


HBM4003 + Tislelizumab showed potentially best-in-class efficacy in MSS CRC patients

Efficacy Endpoint	Efficacy Endpoint (N=23)
ORR	34.8% (8/23)
DCR	60.9% (14/23)
mDoR	8.4m
mPFS	4.2m
mOS	NR
12-m OS Rate	84%


HBM7020 (BCMAxCD3): Global Clinical Development Set to Begin, Targeting a Major Autoimmune Market Opportunity

HBM7020: Superior B-cell depletion with lower CRS risk

- Fully human heavy-chain antibody modules effectively **overcome the challenge of light chain mispairing**
- The asymmetric structure further optimizes the molecule's target cross-linking dependency and selectivity window
- High-specificity binding to BCMA and low-affinity engagement at the CD3 arm enable deep depletion of pathogenic B cells in tissues while **mitigating the risk of CRS**
- Pre-clinical PK/PD shows **deep sustainable depletion of Pathogenic B-Cell** and **favorable tolerability**
- Huge advantage on costs and convenience vs. cell therapies
- Clinically validated TCE platform with a **favorable safety profile**



Preclinical data demonstrate efficient depletion of BCMA-expressing cells, including long-lived plasma cells



Phase I (NCT07649265)

Indication	Systemic lupus erythematosus (SLE), systemic sclerosis (SSc), Sjögren's syndrome, rheumatoid arthritis (RA)
Enrollment	63 patients
Initiation Time	September, 2026
Location	Undisclosed
Clinical Plan	Open-label, multicenter, in two parts: <ul style="list-style-type: none">• Part 1: Low-dose administration in healthy subjects evaluating safety (including CRS, IRR, etc.)• Part 2: Evaluating trends in changes from baseline across different biomarkers in enrolled patients

■ ■ ■ LET003 (ACVR2A/2B): First AI-Enabled Molecule with Superior Preclinical Data on Fat Reduction and Lean Mass Preservation

LET003: Superior Preclinical Data on Fat Reduction and Lean Mass Preservation

- ❑ LET003 exhibited **superior pharmacokinetic characteristics** compared to multiple competitor molecules
- ❑ When combined with semaglutide, LET003 significantly enhanced fat reduction while effectively preserving lean mass
- ❑ LET003 achieved lean mass-promoting effects at lower dose level comparable to bimagrumab at higher dose level, highlighting its potential to become a **best-in-class** therapy for obesity treatment
- ❑ LET003 exhibits **favorable safety profiles** and is well tolerated in Rat and Monkey

2026.05

Preclinical Data Readout




2026Q3

China IND Submission


ACVR2A/2B

ACVR2A/2B




LET003 Has the Best PK Profile among All Tested ACVR2A/2B Blockers

Human FcRn KI Mouse




Cynomolgus PK




- The clearance rate of LET003 is the slowest among all disclosed ACVR2A/2B binders

LET003 Shows Potent Lean Mass-Promoting Activity

% Change of Body Weight



% Change of Lean Mass



- Mice received weekly subcutaneous injection at different dose levels
- With normal diet feeding, lean mass growth contributes more than fat accumulation
- Treatment with 5 mpk LET003 promoted lean mass to a comparable extent as 15 mpk Bimagrumab

BBB Shuttle Platform Drives Next-Gen CNS Innovation, Leading the \$100B+ Global CNS Market

Core Pipelines

Program	Target	Progress	Positioning	Expected Timeline
NEU2005	Undisclosed Target(s)	IND-enabling	BIC molecule in brain shuttle	2027H1 IND expected
NEU3001	Undisclosed Target(s)	Early discovery	FIC molecule with dual brain shuttle	2027H1 PCC expected

TA Head



Eric Liu
MD, PhD

Chief Operating Officer (CNS)
15+ years of global R&D and management experience in CNS



CNS market opportunity
exceeding \$100B

\$155B

Market Size¹

10.4%

CAGR¹

Major indications include Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy, stroke, migraine, depression, schizophrenia, and others

CNS M&A total transaction value
exceeded \$30B in the past year¹

\$30.7B

Johnson
& Johnson



Intra-Cellular
THERAPIES

\$14.6B

NOVARTIS



AVIDITY
BIOSCIENCES

\$12.7B

abbvie



GILGAMESH

\$1.2B

...

...

Multi-Pathway FIC Biologics for Metabolic Diseases, Unlocking a \$100B+ Opportunity across ~2B Patients

Core Pipelines

Program	Target	Progress	Positioning
LET003	ACVR2A/2B	IND-enabling, 2026H2 IND expected	BIC. Enhance and sustain overall body weight loss and fat mass loss. Preserve or maintain lean mass
LET001	Undisclosed Target(s)	PCC-enabling	FIC. Novel MOA based on genetic biomarker. LYTAC mechanism drives superior target elimination
LET004	Undisclosed Target(s)	PCC-enabling	FIC. Preserve or enhance lean mass

Obesity & Metabolic market opportunity exceeding \$70B

\$77.2B

Market Size¹

7.8%

CAGR¹

Major indications include obesity, type 2 diabetes (T2D), metabolic dysfunction-associated steatohepatitis (MASH), etc.

TA Head & Scientific Advisor



Bob Zhang
PhD

President (Metabolic)
20+ years of experience in R&D and management in obesity & metabolic



Lloyd Klickstein
PhD

Member of SAB²
20+ years of experience in R&D and management in obesity & metabolic



Obesity & Metabolic M&A total transaction value exceeded \$20B in the past year¹

\$20B



1. Data Source: Grand View Research, Metabolic Disorder Therapeutics Market Size, Share & Trends Analysis Report, 2025
2. SAB: Scientific Advisory Board



Nona Biosciences -
Harbour BioMed's **AI-native TechBio**
“**GPU**” Chip Technology Platform for
Antibody Drug Development



280+

Global Employees

83%+

R&D and AI Experts



PRIX GALIEN USA

Nona Biosciences shortlisted for the
2025 & 2026 Prix Galien Award
for “**Best Startup**”

4 Proprietary Technology Platforms

Platform

- TCE, CAR-T, mRNA, ADC

The world's largest and most efficient fully
human heavy-chain antibody AI platform

Partner

150+

Cumulative Partners¹

400+

Cumulative Programs¹

Project

20² >> 25+

Clinically-Validated Molecules
Further Increased¹

Financial

> \$46M³ (YoY ~4x)


(~RMB **320M**)

2026H1 Revenue and Growth

Advancing Technology Platforms with Next-Gen Antibody Engineering

Technology Cluster to Solidify Long-Term Competitive Advantage

Building a **Diverse** and **Advanced** Technology Portfolio



AI-Native Innovation Ecosystem Infrastructure Empowering the Development of Next-Gen Complex Molecule



HCAbLM: The World's Exclusive Fully Human HCAb Foundation Model for Efficient Antibody Design and Optimization

- ✓ Trained on **100M+ proprietary fully human HCAb sequences** — the world's first fully human HCAb antibody large language model
- ✓ **Encoder-only Transformer + masked language modeling (MLM)** to learn HCAb-specific sequence and functional features
- ✓ End-to-end empowerment of the full antibody development workflow: **antibody design → drugability screening → multi-objective optimization**


Nona Genx
Generative Antibody Design Platform
AI-driven de novo design for precise antigen targeting

Nona Devx
Antibody Drugability Analysis & Screening Platform
AI-enabled prediction to avoid drugability risks

Nona Optx
Multi-Objective Antibody Engineering Optimization Platform
AI × Automation driving a DBTL closed-loop optimization

AI Notebook: Nona Biosciences' AI-Native Antibody R&D Workspace

Nona Biosciences and Lonza Enter a Strategic Collaboration to Develop Best-in-Class BBB-Crossing Technology for CNS Diseases



Collaboration

Co-developing BIC BBB-crossing technology for the treatment of CNS diseases



Establishing a **BIC** BBB-crossing technology



Enabling **efficient delivery** of a diverse range of novel therapeutic modalities to the CNS



Unlocking new opportunities in **CNS drug development** and **technology licensing**

Terms

Upfront + Option Payments



Nona is entitled to receive **upfront** and **option payments** from Lonza

Platform Licensing → Revenue Sharing



The parties will **share revenues** generated from future **platform licensing agreements** pursuant to the collaboration



A Diversified Partnership Business Model Driving Rapid Growth through an Extensive Partner Network

Business Model



Strategic
Collaboration



Co-Development



Out-Licensing



Technology
Service

Diversified

Partnership Business
Model

133¹ >> 150+

Cumulative Partners

20¹ >> 25+

Clinically-Validated
Molecules

Pharma

Lonza



abbvie

moderna



sanofi



MERCK

Lilly



J&J



...

Biotech

Visterra



Atossa
THERAPEUTICS



Invetx



MYTHIC
THERAPEUTICS



...

Academia

UAB THE UNIVERSITY OF
ALABAMA AT BIRMINGHAM



Yale



...

1. As of December 31, 2025

Total BD Value Exceeding \$13B, Leading the New Paradigm of Global Collaboration

Long-term strategic alliances w MNCs and leading biotech validate our **sustainable** and **scalable** business model, forging a **high-visibility** and **high-growth** revenue base

Strong back-end downstream economics retained by HBM: milestones + royalties + equity stakes in NewCos + GC rights



MNC Strategic Alliances



Potential **10-yr** Strategic Co-Co¹, focusing on Immu & Onco

Global Strategic Co-Co, focusing on Immu

First in-depth collab. with a global pharma from Asia-Pacific

- **3rd** collaboration
- **\$175M** upfronts, near-terms upon option exercise
 - ✓ **\$4.5B** first-year biobuck
- **\$105M** equity investment at premium (37.5%)
- **Beijing Innovation Center**

- **Multiple** Multi-specific antibody discovery programs
- **\$1.1B+** Biobuck
 - ✓ **\$90M** total payments
 - ✓ **\$1.04B+** future milestones
- **China PoC** stage by HBM

- HBM7020 **BCMA x CD3 out-licensing**
- **\$670M+** Biobuck
 - ✓ **\$47M** upfront + near-term payment
 - ✓ **\$623M+** future milestones
- **Platform licensing** agreement with Visterra²



NewCo Formation w/ Top Ventures



Advancing the **first** fully-human ULA TSLP into global Ph III

Novel anti-CTLA-4 with **BIC** potential in MSS CRC

- **ULA** TSLP with **BIC** potential
- **~\$400M** funded → global ph3 for asthma
- **\$970M** Biobuck
 - ✓ **\$45M** upfront + near-term milestone
 - ✓ Minority equity holder (<5%)
- Retain **Greater China rights**

- Novel CTLA-4 - **BIC** efficacy in MSS CRC combo w/ PD-1
- **\$1.2B** Biobuck, with **\$105M +** upfront consideration
 - ✓ **\$55M** upfront and near-term cash payments
 - ✓ **\$50M+** equity stake
- Retain **Greater China rights**

AstraZeneca Strategic Alliance: A Paradigm for Next-Gen Co-Co Model across All Therapeutic Areas, Steadily Advancing Co-Co Programs

HARBOUR
BIOMED



AstraZeneca

\$175M

Upfront + Near-term milestone + Option exercise fee

\$4.4B

Potential future milestones and tiered royalties

Potential **10** years collaboration

Initiate **multiple** programs annually with option to license at predefined stages

Launched in March 2026 at Beijing International

BioPark



First-Year Biobuck



Collaboration Term



Beijing Innovation Center

Steadily advancing preclinical co-co programs with AstraZeneca across multiple disease areas

Sustainable Co-Co Model with AstraZeneca via Strategic Equity Investment¹

Secure long-term **non-dilutive R&D funding** for financial stability, and accelerates blockbuster molecule development via MNCs' global networks



BMS Strategic Alliance: Developing Next-gen Multi-Specific Antibodies

Global Collaboration Focusing on Immunological Diseases: From Discovery to Clinical Development



Collaborate to Advance and Accelerate

Multi-Specific

antibody discovery programs

Advancing **Multiple** preclinical programs

Payments could total **\$90M**

Up to **\$1.035B**

Development and commercial milestones + Tiered royalties if BMS elects to advance all potential programs


Possibility to accelerate programs by conducting

**Early Clinical Trials
(Phase II)**

in **China** by **HBM**



Collaboration Scope and Progress



Financial Terms



Collaboration Highlights



Harbour BioMed and BioMap Jointly Initiate MegaStream TechBio:

The World's Only "AI × Biotech" Dual-Native Biopharmaceutical Company

HARBOUR
BIOMED



BioMap 百图生科

A Global Leading Company in Programmable Complex Molecule Innovative Therapeutics

Exclusive Dataset × Purpose-Built Large Models × Large-Scale Innovative Pipeline Portfolio

Redefining the foundational
engineering paradigm for
complex biologics — with a
new model, new efficiency,
and new pace

- **100B+** parameter AI foundation model
- **~10M** HCAb sequence library
- **Tens of thousands** of wet-lab-validated, multi-dimensional proprietary datasets

Pioneering the first AI-
native intelligent dry-wet
closed-loop laboratory,
driving exponential iteration
of the dry-wet closed loop

- **>500%** experimental efficiency gain vs. prior closed loop
- From weeks to **hours** (design to experiment completion)
- **10X+** data accumulation efficiency gain
- **>5PB** of AI-ready data accumulated within 5 yrs


Scaling up pipeline
portfolios to reshape the
global treatment landscape
with innovative products

- **Multiple** FIC/BIC programs advancing in parallel
- **4** key disease areas: cardiovascular · renal · anti-aging · oncology



Diversified Revenue Mix for High-Visibility, Sustainable Growth with Reduced Risk

Scaling revenue while lowering single-product development risk



Future Revenue Drivers

- **2 products (>3 indications) in global multicenter trials** by end-2027 —UAL anti-TSLP (Autoimmune) & Novel anti-CTLA-4 (Porustobart); **Explore China commercialization with partners**
- Nona Biosciences: **≥50%** organic growth p.a.
- BD becoming a **recurring revenue** stream — **≥2** product collaborations signed & delivered annually
- **Ongoing molecule nomination & delivery** under platform partnerships with **AstraZeneca & Bristol Myers Squibb**
- **\$13B** BD portfolio gradually converting into **milestone revenue**
- **Appreciation of equity stakes** held in NewCos

In 2026H1, We Delivered Steady Revenue Growth while Scaling R&D Investment to Reinforce Long-Term Value


Financial Highlights

- 2026 H1 revenue of **\$122M** (~RMB **834M**), **+21%** YoY. Molecule licensing & strategic collaboration fees +21% YoY, driven by deepened strategic collaborations with MNCs and incremental contributions from out-licensing and collaboration agreements. Research & technology licensing fees +24% YoY, continuing to monetize platform value.
- 2026 H1 adjusted net profit¹ of **\$71.6M** (~RMB **488M**), supported by robust revenue growth and continued operating efficiency improvements.
- 2026 H1 R&D expense of \$29.6M (~RMB 202M), +65% YoY, driven by continued advancement of clinical pipeline programs and expansion of early-stage research programs.

Revenue Breakdown

Adjusted Net Profit¹

R&D Expense



1. Net profit adjustments include share-based compensation, litigation expenses, and fair value change losses, etc.

■ Abundant Liquidity and an Efficient Capital Allocation Plan to Drive ■ Efficient, High-Quality Growth

> RMB 2.4B

(\$360M)

Cash Reserves as of 2026H1

> RMB 1.3B

Bank Credit Facilities as of 2026H1

~RMB 4B in total liquidity, providing
strong support for strategic execution



2026 Capital Allocation Plan



Active Share Buybacks to Boost Shareholder Returns

- ✓ Repurchase program of **HK\$540M** since 2025, with **>HK\$270M** executed to date
- ✓ Ranked **No.1 among HKEX 18A innovative drug companies** in executed buyback value



Doubling Down on Proprietary R&D for Breakthrough Innovation

- ✓ **3–5** high-potential programs to IND annually to ensure a robust R&D pipeline
- ✓ Accelerate at least **1** star program to POC to speed up innovation translation



Advancing Mid-to-Late-Stage Assets and Widening Global Reach

- ✓ Leverage **strategic collaborations & co-development** to advance mid-to-late-stage products in global MRCTs
- ✓ Import **global leading products & technologies** to rapidly enrich mid-to-late-stage pipelines

Catalysts and Priorities in 12 Months



6 Pipeline Progress & Data Readout

HBM9378/WIN378
ULA TSLP mAb

Phase
II/III

Asthma: Global Ph2 (POLARIS) interim data (2026Q3); Global Ph3 initiation (2026Q4)

COPD: Global Ph2 (SIRIUS) (2026Q2)

HBM9161
Batoclimab

BLA

China BLA Approval

HBM7020
BCMAxCD3

Phase I

Global Ph1 initiation

HBM7022
CLDN18.2xCD3

Phase I

Global Ph1 data and Global Ph2 initiation (2027)

HBM4003
Novel CTLA-4

Phase II

Partner to be disclosed (YE2026)

3 INDs Completed & More INDs to Come

HBM7575 ULA TSLP BsAb

- ✓ AD IND clearance (Mar.2026)
- ✓ Asthma IND clearance (Jul. 2026)

HBM2001 TL1AxIL23p19

- ✓ US IND clearance (Apr. 2026)
- ✓ China IND clearance (Jul. 2026)

HBM7004 B7H4xCD3

- ✓ US IND clearance (May 2026)
- ✓ China IND clearance (Aug. 2026)

J9003 Undisclosed Target

IND submission (2026H2)

LET003 ACVR2A/2B

IND submission (2026H2)

NEU2005 Undisclosed Target

IND submission (2027H1)

BD & Partnership

Multiple ongoing BD out-licensing

deals for clinical / mid-to-late-stage assets — via **ex-Greater**

China licensing, NewCo, Co-Co

models, etc. — laying the foundation for mid-to-short-term

global expansion

Harbour BioMed2028

A Global Leading Platform-Based
BioPharma Group

5+ commercial and near-commercial products¹ with
a global peak sales potential exceeding **RMB 20B**

3+ PoC assets, representing over **\$5B** in global
peak sales potential

3+ INDs annually, with a cumulative
10+ IND submissions planned
over the next 3 years

Revenue sustained at a high CAGR of
50-80%, achieving **RMB 1B**
of recurring revenue

Built a comprehensive, **AI-powered**
antibody engineering platform

Establish sustainable, recurring
partnerships with MNCs, serving as the
foundation for global platform expansion

1. Recurring revenue refers to non-BD generated one-time payments

HARBOUR
BIOMED

2142.HK

Harbour BioMed: Rejoining Stock Connect

Officially Included for Trading
from Sept. 2026

www.harbourbiomed.com
www.nonabio.com

恒生指數有限公司宣佈指數檢討結果 / 3

股票代號	交易所	公司
1236	香港聯交所	深圳樂動機器人股份有限公司
1286	香港聯交所	廣晉精密工業有限公司
1385	香港聯交所	上海復旦微電子集團股份有限公司
1392	香港聯交所	深圳海清智元科技股份有限公司
1440	香港聯交所	應星控股集團有限公司
1511	香港聯交所	股勢科技(北京)股份有限公司
1609	香港聯交所	北京天星醫療股份有限公司
1651	香港聯交所	津上精密機床(中國)有限公司
1672	香港聯交所	歌禮製藥有限公司 - B
1779	香港聯交所	天辰生物醫藥(蘇州)股份有限公司 - B
1866	香港聯交所	中國心連心化肥有限公司
1879	香港聯交所	上海耀智科技股份有限公司 - P
1956	香港聯交所	北京中科聞歌科技股份有限公司
2076	香港聯交所	看準科技有限公司 - W
2142	香港聯交所	和鉑醫藥控股有限公司 - B
2225	香港聯交所	今海醫療科技股份有限公司
2272	香港聯交所	廈門科拓通訊技術股份有限公司
2335	香港聯交所	陝西麥科奧特醫藥科技股份有限公司 - B
2476	香港聯交所	勝宏科技(惠州)股份有限公司
2526	香港聯交所	杭州德通生物科技股份有限公司 - B
2553	香港聯交所	北京首鋼朗澤科技股份有限公司
2616	香港聯交所	基石藥業 - B
2632	香港聯交所	江蘇澤景汽車電子股份有限公司
2670	香港聯交所	北京靈通科技股份有限公司
2672	香港聯交所	白鶴在線(廈門)數字科技股份有限公司
2696	香港聯交所	上海復宏漢霖生物技術股份有限公司
2697	香港聯交所	廣東真健康醫療科技開發股份有限公司 - B
2714	香港聯交所	牧原食品集團股份有限公司
2723	香港聯交所	北京深濟智能科技股份有限公司



Dual Wheel Immunology and Inflammatory Portfolio

Strategic Focus on 3 Core IMM TA – Respiratory, Gastroenterology, Dermatology and Immune Cell Depletion

Modality	Program & Targets	Indication	Discovery	IND	Ph1	Ph2	Ph3/BLA	Territory	Partner	Positioning
mAb	HBM9161 Batoclimab <i>FcRn</i>	gMG						GC (out-licensed)		<ul style="list-style-type: none">China commercial partnered with CSPCChina BLA approval (2026)
mAb	HBM9378 <i>TSLP</i>	 Asthma & COPD					Ph2 Data Readout	Ex-GC (out-licensed ¹)		<ul style="list-style-type: none">Asthma: Ph2 interim data readout (2026Q3), Ph3 initiation (2026Q4)COPD: Ph2 initiated in 2026Q2 (FPI)
		 Asthma & COPD						GC & other countries²		<ul style="list-style-type: none">Ph2 initiation in Asthma/COPD (2026)
bsAb	HBM7575 <i>TSLP x Undisclosed Target</i>	 AD & Asthma						Global¹		<ul style="list-style-type: none">NMPA IND approval for AD (Mar.2026)NMPA IND approval for Asthma (Jul. 2026)Ph1 initiation (Mar. 2026)
bsAb	HBM2001 <i>TL1A x IL23p19</i>	 IBD						Global		<ul style="list-style-type: none">FDA IND approval (Apr.2026)NMPA IND approval (Jul. 2026)
mAb	J9003 <i>Undisclosed Target</i>	 IBD					IND Submission	Global		<ul style="list-style-type: none">Potential FICIND submission (2026H2)

Immune Cell Depletion

bsAb	HBM7020 <i>BCMA x CD3</i>	SLE, SSc, Sjögren's, RA ³					Ph1 Initiation	Ex-GC (out-licensed)		<ul style="list-style-type: none">TCE for Autoimmune diseasesPh1 initiation (2026H2)
bsAb	R2006 <i>CD3 x CD19</i>							Global		<ul style="list-style-type: none">Immune-resetting Next-GEN TCE
tsAb	R7026 <i>CD3 x CD19 x BCMA</i>							Global		<ul style="list-style-type: none">Immune-resetting tsAb TCE
tsAb	R3006 <i>CD3 x CD20 x BCMA</i>							Global		<ul style="list-style-type: none">Immune-resetting tsAb TCE
tsAb	R7027 <i>Undisclosed Target</i>							Global		<ul style="list-style-type: none">Next-gen immune cell depletion



Robust Portfolio of Potentially BIC Pipelines in Oncology, Obesity and CNS

Modality	Program & Targets	Indication	Discovery	IND	Ph1	Ph2	Ph3	Territory	Partner	Positioning
mAb	HBM4003 Porustobart <i>CTLA-4</i>	PD-1 Combo: MEL, NSCLC, HCC, NEN, CRC ¹						Ex-GC (out-licensed)	Solstice Oncology	<ul style="list-style-type: none">• Superior safety vs. Ipilimumab• Combo PD-1 in MSS CRC (BIC)
mAb	HBM1022 <i>CCR8</i>	Solid Tumor						Global		<ul style="list-style-type: none">• FDA IND approval• Next-gen Treg-depleting therapy targeting a novel GPCR
mAb	HBM1007 <i>CD73</i>	Solid Tumor						Global		<ul style="list-style-type: none">• FDA IND approval
TCE	HBM7022/AZ5863 <i>Claudin18.2 x CD3</i>	Solid Tumor						Global (out-licensed)	AstraZeneca 	<ul style="list-style-type: none">• Global Ph1 enrollment target 280 pts• Global Ph1 data (2027H1)
bsAb	HBM9027 <i>PD-L1 x CD40</i>	Pancreatic Cancer						Global		<ul style="list-style-type: none">• Next-gen immuno-oncology asset• NMPA and FDA IND approval
bsAb	HBM7004 <i>B7H4 x CD3</i>	1L+ NSCLC						Global		<ul style="list-style-type: none">• "2+1" TCE combo for solid tumors• NMPA IND approval (May 2026)• FDA IND approval (Aug. 2026)

Next-Gen Therapeutics

tsAb	HBM3001 <i>Undisclosed Target</i>	Solid Tumor						Global		<ul style="list-style-type: none">• Next-gen solid tumor asset
ADC	HBM5002 <i>Undisclosed Target</i>	Solid Tumor						Global		<ul style="list-style-type: none">• Next-gen solid tumor asset
mAb	LET003 <i>ACVR2A/2B</i>	Obesity						Global		<ul style="list-style-type: none">• 1st AI-driven clinical asset• IND submission (2026H2)
Undisclosed	NEU2005 <i>Undisclosed Target</i>	CNS						Global		<ul style="list-style-type: none">• Potential BIC for BBB shuttle• IND submission (2027H1)

1. MEL = Melanoma; NSCLC = Non-Small Cell Lung Cancer; HCC = Hepatocellular Carcinoma; NEN = Neuroendocrine Neoplasm; CRC = Colorectal Cancer